Lymphedema Treatment Market Research Report - Global Forecast till 2025

Lymphedema Treatment Market Research Report - Global Forecast till 2025

ID: MRFR/HC/6968-HCR | November, 2019 | Region: Global | 110 pages | Half-Cooked Research Reports

Market Forecast


Lymphedema Treatment Market is estimated to grow with a CAGR of 4.0%.


Market Synopsis


The increasing prevalence of cancer is expected to drive the Global Lymphedema Treatment Market.


The strong clinical pipeline is likely to boost the market growth. Market players like HERANTIS PHARMA PLC, are developing curative treatment of secondary lymphedema—Lymfactin. Lymfactin is the world’s first and only clinical-stage gene therapy against lymphedema. The market potential of the drug is estimated to be around USD 650 Million.


Market Influencer


Increased research & development in the market is estimated to influence the commercialization in the market. The market is projected to witness a shift from symptomatic treatments to targeted treatment during the forecast period of 2018 to 2025.


Market Drivers



  • Increasing cancer cases


Lymphedema is a medical condition characterized by extra fluid buildup in the body tissues, resulting in a blockage of the lymphatic system.


It is reported that a majority of the lymphedema cases affect cancer patients. The condition can arise immediately after cancer surgery or radiation therapy. However, in certain cases, lymphedema is reported after months or years of cancer treatment. Thus, it is projected that the global lymphedema treatment market will grow, parallelly, to the increasing prevalence of cancer.



  • Favorable reimbursement policies

  • Strong pipeline in the market

  • Government support


Market Restraints




  • Limited availability of the treatment options available in the market.




  • Need to change the compression garments at regular intervals.




  • There is a need to change the compression garments at regular intervals. Such garments have a lifespan of approximately six months. This creates reluctance in lymphedema patients to opt for such treatment options, thus, restricting market growth.




  • Late diagnosis of lymphedema




Segmentation


By Type




  • Primary Lymphedema is caused by the abnormal development of the lymph system. Symptoms may occur at birth or older age. The primary lymphedema segment is estimated to hold the least market share in 2018.




  • Secondary Lymphedema is caused by damage to the lymph system owing to cancer treatment involving surgery, radiation therapy, and others. A majority of the patients suffered from secondary lymphedema making this the leading segment in 2018.




By Affected Area




  • Lower Extremity: Lower extremity lymphedema involves the swelling of ankles, legs, and feet. This segment is estimated to hold a share of 0% in 2018.




  • Upper Extremity: Upper extremity lymphedema is one of the most poorly understood complications of the disease, making the segment to hold a share of 9.0% in the market in 2018.




  • Genitalia: This segment held the least share of the market in 2018.




By Treatment




  • Compression Devices & Bandaging: Compression devices are pumps connected to a sleeve that is then wrapped around the affected area that applies pressure. This helps the fluids to circulate through the lymph vessels and veins.




  • Bandaging involves wrapping, thereby helping in preventing the area from refilling with fluid. Lymphedema that has not improved with other treatments can be treated with bandaging. Thus, compression devices & bandaging segment was the largest segment of the lymphedema treatment market in 2018.




  • Laser Therapy: Laser therapy reduces lymphedema swelling after a mastectomy. The segment is estimated to be one of the fastest-growing segments.




  • Drug Therapy & Surgery: Drug therapy and surgery are the least opted treatment in the market, making the segment to hold the least share in the market.




By End-User




  • Hospitals and clinics: By the end, user, hospitals, and clinics holds the largest market share. Favorable government policies and rising awareness campaigns across the globe are responsible for increasing the number of patients seeking treatment through primary healthcare facilities, i.e., hospitals and clinics.




  • Clinical Research Organizations: A growing segment owing to an increasing number of upcoming treatments.




  • Research & Academic Institutes: Rapid technological advances and research & development collaborations are leading to significant growth by this segment.




By Region




  • Americas: The Americas is the largest regional market owing to the increasing prevalence of cancer and the presence of major market players such as Tactile Medical, in the region. In 2018, around 1,735,350 cases of cancer were diagnosed in the US.




  • Europe: Europe accounted for the second-largest market share in 2018. Rising healthcare expenditure and the presence of developed economies drive the European regional market for lymphedema treatment. It was reported that ~USD 5,490.1 was the per capita healthcare expenditure in Europe in 2016.




  • Asia-Pacific: The fastest-growing regional market for lymphedema treatment. Asia-Pacific has the world’s largest population, and fast-developing healthcare industry whiten countries including China and India.




  • Middle East & Africa: Underdeveloped healthcare infrastructure in the region makes it very difficult for the manufactures to reach their consumers. Moreover, the presence of stringent government regulations restraints market growth.




Key Players



  • 3A Health Care (Italy)

  • Bio Compression Systems, Inc. (US)

  • Devon Medical Products (US)

  • HERANTIS PHARMA PLC (Finland)

  • Lohmann & Rauscher (Germany)

  • Mego Afek Ltd (US)

  • SIGVARIS (Switzerland)

  • Tactile Systems Technology Inc. (US)

  • Wright Therapy Products (BSN Medical) (Germany)

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis


6. GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TYPE

6.1. Overview

6.2. Primary Lymphedema

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.3. Secondary Lymphedema

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7. GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA

7.1. Overview

7.2. Lower Extremity

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.3. Upper Extremity

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.4. Genitalia

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

8. GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TREATMENT

8.1. Overview

8.2. Compression Devices & Bandages

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

8.3. Laser Therapy

Market Estimates & Forecast, by Country, 2019–2025

Market Estimates & Forecast, by Region, 2019–2025

8.4. Drug Therapy

Market Estimates & Forecast, by Country, 2019–2025

Market Estimates & Forecast, by Region, 2019–2025


8.5. Surgery

Market Estimates & Forecast, by Country, 2019–2025

Market Estimates & Forecast, by Region, 2019–2025

8.6. Others

Market Estimates & Forecast, by Country, 2019–2025

Market Estimates & Forecast, by Region, 2019–2025

9. GLOBAL LYMPHEDEMA TREATMENT MARKET, BY END USER

9.1. Overview

9.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

9.3. Clinical Research Organizations

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

9.4. Research & Academic Institutes

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

10. GLOBAL LYMPHEDEMA TREATMENT MARKET, BY REGION

10.1. Overview

10.2. Americas

10.2.1. North America

10.2.1.1. US

10.2.1.2. Canada

10.2.2. Latin America

10.3. Europe

10.3.1. Western Europe

10.3.1.1. Germany

10.3.1.2. France

10.3.1.3. Italy

10.3.1.4. Spain

10.3.1.5. UK

10.3.1.6. Rest of Western Europe

10.3.2. Eastern Europe

10.4. Asia-Pacific

10.4.1. Japan

10.4.2. China

10.4.3. India

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Middle East & Africa

10.5.1. Middle East

10.5.2. Africa

11. COMPANY LANDSCAPE

11.1.1. Overview

11.1.2. Competitive Analysis

12. COMPANY PROFILES

12.1. 3A Health Care (Italy)

12.1.1. Company Overview

12.1.2. Type Overview

12.1.3. Financial Overview

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Bio Compression Systems, Inc. (US)

12.2.1. Company Overview

12.2.2. Type Overview

12.2.3. Financial Overview

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. Devon Medical Products (US)

12.3.1. Company Overview

12.3.2. Type Overview

12.3.3. Financial Overview

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. HERANTIS PHARMA PLC (Finland)

12.4.1. Company Overview

12.4.2. Type Overview

12.4.3. Financial Overview

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Lohmann & Rauscher (Germany)

12.5.1. Company Overview

12.5.2. Type Overview

12.5.3. Financial Overview

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Mego Afek Ltd (US)

12.6.1. Company Overview

12.6.2. Type Overview

12.6.3. Financial Overview

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. SIGVARIS (Switzerland)

12.7.1. Company Overview

12.7.2. Type Overview

12.7.3. Financial Overview

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Tactile Systems Technology Inc. (US)

12.8.1. Company Overview

12.8.2. Type Overview

12.8.3. Financial Overview

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Wright Therapy Products (BSN Medical) (Germany)

12.9.1. Company Overview

12.9.2. Type Overview

12.9.3. Financial Overview

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Others

13. APPENDIX

13.1. References

13.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL LYMPHEDEMA TREATMENT MARKET SYNOPSIS, 2019–2025

TABLE 2 GLOBAL LYMPHEDEMA TREATMENT MARKET ESTIMATES & FORECAST, 2019–2025 (USD MILLION)

TABLE 3 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 4 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2019–2025 (USD MILLION)

TABLE 5 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 6 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 7 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY REGION, 2019–2025 (USD MILLION)

TABLE 8 NORTH AMERICA: LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 9 NORTH AMERICA: LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2019–2025 (USD MILLION)

TABLE 10 NORTH AMERICA: LYMPHEDEMA TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 11 NORTH AMERICA: LYMPHEDEMA TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 12 US: LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 13 US: LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2019–2025 (USD MILLION)

TABLE 14 US: LYMPHEDEMA TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 15 US: LYMPHEDEMA TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 16 CANADA: LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 17 CANADA: LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2019–2025 (USD MILLION)

TABLE 18 CANADA: LYMPHEDEMA TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 19 CANADA: LYMPHEDEMA TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 20 LATIN AMERICA: LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 21 LATIN AMERICA: LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2019–2025 (USD MILLION)

TABLE 22 LATIN AMERICA: LYMPHEDEMA TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 23 LATIN AMERICA: LYMPHEDEMA TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 24 EUROPE: LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 25 EUROPE: LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2019–2025 (USD MILLION)

TABLE 26 EUROPE: LYMPHEDEMA TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 27 EUROPE: LYMPHEDEMA TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 28 WESTERN EUROPE: LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 29 WESTERN EUROPE: LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2019–2025 (USD MILLION)

TABLE 30 WESTERN EUROPE: LYMPHEDEMA TREATMENT MARKET, BY TREATMENTT, 2019–2025 (USD MILLION)

TABLE 31 WESTERN EUROPE: LYMPHEDEMA TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 32 EASTERN EUROPE: LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 33 EASTERN EUROPE: LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2019–2025 (USD MILLION)

TABLE 34 EASTERN EUROPE: LYMPHEDEMA TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 35 EASTERN EUROPE: LYMPHEDEMA TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 36 ASIA-PACIFIC: LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 37 ASIA-PACIFIC: LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2019–2025 (USD MILLION)

TABLE 38 ASIA-PACIFIC: LYMPHEDEMA TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 39 ASIA-PACIFIC: LYMPHEDEMA TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA: LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA: LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2019–2025 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA: LYMPHEDEMA TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA: LYMPHEDEMA TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL LYMPHEDEMA TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL LYMPHEDEMA TREATMENT MARKET

FIGURE 4 GLOBAL LYMPHEDEMA TREATMENT MARKET SHARE, BY TYPE, 2018 (%)

FIGURE 5 GLOBAL LYMPHEDEMA TREATMENT MARKET SHARE, BY AFFECTED AREA, 2018 (%)

FIGURE 6 GLOBAL LYMPHEDEMA TREATMENT MARKET SHARE, BY TREATMENT, 2018 (%)

FIGURE 7 GLOBAL LYMPHEDEMA TREATMENT MARKET SHARE, BY END USER, 2018 (%)

FIGURE 8 GLOBAL LYMPHEDEMA TREATMENT MARKET SHARE, BY REGION, 2018 (%)

FIGURE 7 AMERICAS: LYMPHEDEMA TREATMENT MARKET SHARE BY REGION, 2018 (%)

FIGURE 9 NORTH AMERICA: LYMPHEDEMA TREATMENT MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 10 EUROPE: LYMPHEDEMA TREATMENT MARKET SHARE, BY REGION, 2018 (%)

FIGURE 11 WESTERN EUROPE: LYMPHEDEMA TREATMENT MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 12 ASIA-PACIFIC: LYMPHEDEMA TREATMENT MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 13 MIDDLE EAST & AFRICA: LYMPHEDEMA TREATMENT MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 14 GLOBAL LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2018 (%)

FIGURE 15 3A HEALTH CARE: KEY FINANCIALS

FIGURE 16 3A HEALTH CARE: SEGMENTAL REVENUE

FIGURE 17 3A HEALTH CARE: REGIONAL REVENUE

FIGURE 18 BIO COMPRESSION SYSTEMS, INC.: KEY FINANCIALS

FIGURE 19 BIO COMPRESSION SYSTEMS, INC.: SEGMENTAL REVENUE

FIGURE 20 BIO COMPRESSION SYSTEMS, INC.: REGIONAL REVENUE

FIGURE 21 DEVON MEDICAL PRODUCTS: KEY FINANCIALS

FIGURE 22 DEVON MEDICAL PRODUCTS: SEGMENTAL REVENUE

FIGURE 23 DEVON MEDICAL PRODUCTS: REGIONAL REVENUE

FIGURE 24 HERANTIS PHARMA PLC: KEY FINANCIALS

FIGURE 25 HERANTIS PHARMA PLC: SEGMENTAL REVENUE

FIGURE 26 HERANTIS PHARMA PLC: REGIONAL REVENUE

FIGURE 27 LOHMANN & RAUSCHER: KEY FINANCIALS

FIGURE 28 LOHMANN & RAUSCHER: SEGMENTAL REVENUE

FIGURE 29 LOHMANN & RAUSCHER: REGIONAL REVENUE

FIGURE 30 MEGO AFEK LTD: KEY FINANCIALS

FIGURE 31 MEGO AFEK LTD: SEGMENTAL REVENUE

FIGURE 32 MEGO AFEK LTD: REGIONAL REVENUE

FIGURE 33 SIGVARIS: KEY FINANCIALS

FIGURE 34 SIGVARIS: SEGMENTAL REVENUE

FIGURE 35 SIGVARIS: REGIONAL REVENUE

FIGURE 36 TACTILE SYSTEMS TECHNOLOGY INC.: KEY FINANCIALS

FIGURE 37 TACTILE SYSTEMS TECHNOLOGY INC.: SEGMENTAL REVENUE

FIGURE 38 TACTILE SYSTEMS TECHNOLOGY INC.: REGIONAL REVENUE

FIGURE 39 WRIGHT THERAPY PRODUCTS (BSN MEDICAL): KEY FINANCIALS

FIGURE 40 WRIGHT THERAPY PRODUCTS (BSN MEDICAL): SEGMENTAL REVENUE

FIGURE 41 WRIGHT THERAPY PRODUCTS (BSN MEDICAL): REGIONAL REVENUE



This table of content is tentative and subject to change as the research progresses.

Please note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.